Home / About / Governance / Board of Directors

Board of Directors

The Board of Directors oversees the management, strategic direction and financial accountability of the Network. The Board approves GlycoNet’s policies and procedures to adhere to Network goals and mission. It is also responsible for the membership and the makeup of committees. The Board receives input from seven Board Committees: the Executive Committee, the Finance & Audit Committee, the Nominating Committee, the Research Management Committee, the Commercialization & Legacy Committee, the EDI Committee, and the Training Committee.


Members of the Board

A highly-recognized Canadian life sciences leader, Karimah brought 30 years of dynamic global business experience to her role as CEO and Partner at Quark Venture. She previously held the position of CEO at CDRD, where she was responsible for ensuring the organization’s long-term sustainability, while leading its business functions and successfully building the many national and international alliances and strategic partnerships which were contributing significantly to advancing the goals of CDRD.

Samuel currently serves as a Strategic Advisor to Western Economic Diversification, and as a board member to Inspire Health, the Institute for Health Systems Transformation and Sustainability, and the Vancouver Prostate Centre, as well as a member of the Scientific Advisory Board of Quest Pharma and as a Key Opinion Leader for Quark Venture Inc.

Christine is a science executive with over 25 years of investment, advisory, business development and marketing experience. She is an expert in translating scientific data into market potential and concrete company strategy. Most recently Managing Partner and Founder of Scientia Advisors and Investments where she advised and facilitated fundraising for emerging life sciences companies, Christine has extensive experience in capital markets, strategic planning and analysis.

Janice Bailey has been the Scientific Director of the Fonds de recherche du Québec – Nature and Technologies (FRQNT) since 2019. The mandate of the FRQNT is to develop and promote research activities to solve challenges
and stimulate socio-economic development in a manner that will benefit Quebec and other nations. In doing so, the FRQNT prioritizes interdisciplinary international collaboration, research partnerships, and diversity in its approaches.

Louise St-Onge is the Head of Pricing, Market Access & Government Affairs at Mitsubishi Tanabe Pharma Canada.  She is an accomplished Pharma Leader with >25 years executive experience and track record of achievements in Complex Specialty Pharma.  Recognized as a change agent, she brings unique perspectives gained from her broad commercial & patient access experience, including in setting up Canadian Operations.

Christopher’s practice focuses on mergers and acquisitions and finance transactions, as well as advising on governance and general corporate and securities law matters. His clients include private equity and venture capital funds and companies ranging from publicly traded multinationals to early-stage ventures manufacturing.

With more than 20 years of international experience in both the academic and private sectors, Catalina Lopez-Correa’s deep understanding of genomics and innovation has inspired leaders in science and industry to collaborate toward solving some of the world’s greatest challenges. Dr. Lopez-Correa holds a Medical degree from the UPB in Colombia, a Master’s degree in Human Genetics from Paris V University in France, a PhD in Medical Biosciences from the KULeuven in Belgium, a mini MBA from McGill University in Canada and has trained in innovation leadership at Singularity University.


Nils is a Fellow of the Chemical Institute of Canada. He currently serves as a member of three boards of not-for-profit organizations including Compute Canada, TECTERRA, and the Canadian Light Source (CLS) for which he is Chair of the Board. He recently finished terms as a member of the boards of ArboraNano, a Business-led NCE, the California Nanosystems Institute (CNSI), and the Pacific Institute for Mathematical Sciences, and as Chair of the Board of NSERC’s Strategic Network program BiopSys at the University of Toronto.

Norma has extensive experience over a 28-year career with Merck in Sales, Marketing, Strategic Planning, Corporate Affairs, Pharmacoeconomics, Health Education and Training, Government Relations, Operations and Policy and Patient Access. Most recently she was involved in developing and management of key partnerships for Merck in Health Information Technology, and Health Data Science along with Life Sciences Accelerators/Research collaborations.

Mariela is an immunologist and Professor at the University of Montreal. She is known for research in the areas of infectious diseases and the underlying innate and adaptive immune responses, with a particular focus on the interactions of encapsulated streptococci (such as Streptococcus suis and Group B Streptococcus) with the components of the immune system.

Dr. Acker is the Associate Vice-President (Research Integrity Support) where he has leadership responsibilities for building, implementing and managing a framework that supports programs and services encompassing all research integrity areas, including compliance, ethics certification, clinical trials monitoring, human and animal ethics, safeguarding research, and legal requirements related to research at the University of Alberta.

Warren is a Professor from the Department of Biological Sciences at the University of Alberta. The Wakarchuk lab investigates the structure and function of the enzymes which make and degrade various glycoconjugates. This work has been enabling the chemo-enzymatic synthesis of bioactive glycoconjugates both in the laboratory and for industrial projects. The Wakarchuk lab has expertise with both mammalian and bacterial carbohydrate active enzymes for glycan remodelling applications.

Dr. Plante is Senior Director of Bacterial Immunology at Moderna Therapeutics where he leads the discovery of novel mRNA-based vaccines and antibodies. Previously, Dr. Plante served as Director of Research at Visterra through their acquisition by Otsuka for $430M. At Visterra he led early stage research programs including a CARB-X funded program developing an innovative glycan-targeted antibody-drug conjugate for the treatment of Pseudomonas aeruginosa infections.

Dr. Borovina is a Managing Director on the investment banking team at Bloom Burton where she leads the firm’s scientific ideation team and management consulting practice, providing clients with advice on scientific, clinical and capital markets strategy. Dr. Borovina has been with Bloom Burton since 2014 and has held several positions in the firm, most recently as an analyst on the equity research team, where she researched publicly traded healthcare companies and made investment recommendations. Prior to joining Bloom Burton, she gained business development experience while working for GeneYouIn, a direct-to-consumer genetic testing startup. Dr. Borovina currently serves on the Emerging Companies Advisory Board of BIOTECanada, the national biotechnology industry association.

Dr. Ghanei brings over 10 years of experience in business development and venture formation. He has a successful track record of managing and leading transactions with licensing and mergers and acquisitions deals worth over $1.5 billion. He has generated over 500 new business leads, resulting in portfolio expansions and increasing revenue potential by 800%. Dr. Ghanei has a deep knowledge of the various aspects of the pharmaceutical industry, and he excels in building partnerships and leading cross-functional teams in complex projects.

Dr. Jolie is a highly accomplished veterinarian with a diverse academic and professional background. She obtained her Doctor of Veterinary Medicine degree from the University of Ghent, Belgium, and pursued further studies, including internships and research assistantships. Dr. Jolie’s extensive academic journey includes a residency in Swine Medicine and a PhD focusing on airborne contaminants’ impact on swine respiratory health. Over the past 12+ years, she has held significant roles at Pfizer Animal Health and Merck Animal Health, showcasing her expertise in the field and culminating in the completion of an Executive MBA. At Merck Animal Health, she has led pivotal roles, including heading the Global Swine division, shaping strategic direction and ensuring product alignment to meet global market needs.


Elizabeth is the CEO of GlycoNet. She was involved in the GlycoNet initiative since the Letter of Intent stage and served as the Associate Director, Business for the Alberta Glycomics Centre from 2007–2015. Prior to her position with the Centre, she worked as a manager of large-scale and multi-institutional projects with Genome Prairie. In addition to her PhD in biochemistry, Elizabeth has an MBA in biotechnology management.

Terms of Reference

View Terms of Reference (PDF)

Canadian Glycomics Network
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
Tel: 780-492-6204
Fax: 780-492-4147

Subscribe to GlycoNet’s Newsletter


Scroll to Top